Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma

Cancer

Volumn 117, Issue 14, 2011, Pages 3187-3192

  Sun, Weijing ^a,b   Sohal, Davendra ^a   Haller, Daniel G ^a   Mykulowycz, Kristine ^a   Rosen, Mark ^b   Soulen, Michael C ^b   Caparro, Millie ^a   Teitelbaum, Ursina R ^a   Giantonio, Bruce ^a   O'Dwyer, Peter J ^a   Shaked, Abraham ^b   Reddy, Rajender ^b   Olthoff, Kim ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

advanced; anti angiogenesis; bevacizumab; capecitabine; chemotherapy; cirrhosis; hepatocellular carcinoma; metastatic; oxaliplatin; phase 2

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER SURGERY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SENSORY NEUROPATHY; SEPSIS; STOMACH PERFORATION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 79959978255     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25889     Document Type: Article

References (21)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108. (Pubitemid 40372904)
2. El Serag HB, Mason AC., Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745-750. (Pubitemid 29114292)
3. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 1676-1681. (Pubitemid 29334445)
4. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008; 112: 2733-2739. (Pubitemid 351969218)
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
6. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009; 27: 843-850.
7. Zhu AX, Fuchs CS, Clark JW, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 1898-1903. (Pubitemid 46638989)
8. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004; 101: 578-586. (Pubitemid 38970609)
9. Cheng AL, Yang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
10. Cantarini MC, Trevisani F, Morselli-Labate AM, et al., Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006; 101: 91-98. (Pubitemid 43381714)
11. Hatanaka K, Kudo M, Fukunaga T, et al. Clinical characteristics of NonBNonC-HCC: comparison with HBV and HCV related HCC. Intervirology. 2007; 50: 24-31. (Pubitemid 46005268)
12. Toshikuni N, Izumi A, Nishino K, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009; 24: 1276-1283.
13. Trevisani F, Mangini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007; 102: 1022-1031. (Pubitemid 46698223)
14. Ferrara N, Davis-Smyth T., The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4-25. (Pubitemid 27076453)
15. Jenab-Wolcott J, Giantonio BJ., Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009; 9: 507-517.
16. Xiong YQ, Sun HC, Zhu XD, et al. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol. Published online May 21, 2010.
17. Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010; 102: 981-876.
18. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26: 2992-2998.
19. Qin S, Bai Y, Ye S, et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients [abstract]. J Clin Oncol. 2010; 28: 4008.
20. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007; 97: 862-867. (Pubitemid 47519302)
21. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007; 109: 1384-1390. (Pubitemid 46466566)